ArticleChemical & biomedical imaging2026
APT MRI Signature for Risk Stratification of Pediatric Medulloblastoma.
Article in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging from Macro to Nanoscale: Multimodal Advances in Chemical and Biomedical Imaging.Chemical & biomedical imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medulloblastoma (MB), a malignant intracranial tumor, is classified into four molecular subgroups (WNT, SHH, Group 3, Group 4) with distinct risk profiles. This study aimed to establish APT MRI-based radiomic signature for distinguishing risk subgroups of pediatric MB. From February 2018 to May 2023, 72 diagnosed pediatric MB patients were enrolled, all undergoing brain MRI examinations. Radiomic features were extracted from regions of interest in APT-related metric maps and structural MR images, and were subject to a feature selection process. The performance of retained individual features and radiomic signatures generated via the least absolute shrinkage and selection operator (LASSO) was assessed using receiver operating characteristic (ROC) analysis. Final analysis included 56 subjects (mean age: 76.5 ± 41.9 months; 37 males), consisting of 7 WNT, 17 SHH, 9 Group 3, and 23 Group 4 cases. The optimal individual radiomic feature exhibited an area under the ROC curve (AUC) of 0.83 for risk stratification, while the APT-based radiomic signature achieved a higher AUC of 0.86. Notably, structural images and clinical factors failed to provide additional value to the APT-based signature for risk stratification. In conclusion, APT MRI-based radiomic signature demonstrated favorable performance in distinguishing risk groups of pediatric MB, offering valuable insights for clinical diagnosis of MB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.